Medable Inc.
a leading provider of the end-to-end platform for digitally enabled and
data-driven clinical trials, today announced it has been awarded two
Fast-Track Small Business Innovation (SBIR) grants from the National
Cancer Institute (NCI). The grants will provide up to $3.5 million in
nondilutive research funding over the next several years.
The first award provides funding to develop TogetherCare (Track Outcomes
& Guidance, Technology for Health and Effective Resources), a mobile
application on a smart software system that informal caregivers will use
to develop and implement home-based care for cancer survivors. This
mobile application will help alleviate the cancer caregiving burden and
facilitate communication with patients’ healthcare teams by centering
the conversation around a care plan. The goal of this Fast-Track project
is to develop and validate a final TogetherCare mobile app that can be
immediately used in health care settings.
The ultimate aim of this project is to provide a product that promotes
engagement of all stakeholders to plan for care through an integrated
and dynamic care plan with resources and communication pathways for care
at any stage in the cancer or other disease continuums.
The second award will fund the development of DigiBioMarC (Digital
BioMarkers for Clinical Impact), a scalable and flexible cloud-based
platform to capture and analyze wearable, implantable, or external
device data. This platform also provides an informatics tool for
automated data aggregation, integration, and machine learning
algorithms. It is based on the scalable user-centered Medable platform,
which implements standardization and normalization of patient-generated
data to drive health insights.
This second Fast-Track project will focus on product development with an
ultimate aim of a product that improves cancer research data and
clinical trials, enhances clinical care, and that can be used to easily
engage patients in preventive health behaviors and treatment adherence.
“The SBIR program is incredibly competitive and winning these awards are
another validation of Medable’s industry-leading, intelligent end-to-end
cloud platform that provides a unified, flexible suite of tools where
patients, providers, CROs and sponsors can work together as an effective
clinical trial team,” said Dr. Michelle Longmire, Medable CEO and
co-founder. “We are the only health platform company providing health
prediction and precision across massive mobile app datasets, and these
funds will support the development of new products that have the
potential to improve patient outcomes. As a leader in global clinical
trial innovation, we want to enable a transformation to better
understand human health.”
About Medable
Medable is a privately held, venture-backed company headquartered in
Palo Alto, California. Medable is on a mission to get effective
therapies to patients faster by dramatically reducing the time from
therapeutic development to market realization with digital data capture
and real-time analytics that remove the complexities of clinical
research to dramatically reduce trial timelines. Medable is pioneering a
new category of life science technologies that replace the stagnant and
siloed data of traditional ePRO, eCOA, EDC, and eSource with an
intelligent and unified end-to-end (E2E) platform for clinical trial
execution. Our E2E platform allows patients, healthcare providers,
clinical research organizations and pharmaceutical sponsors to work
together as a connected and empowered team in clinical trials and
research.
For more information, visit www.medable.com and
follow Medable on Twitter: @Medableinc
View source version on businesswire.com: https://www.businesswire.com/news/home/20190416005344/en/